In September 2014, the U.S. Food & Drug Administration (FDA) warned that the injectable asthma drug Xolair had been linked to an increased risk for heart attacks and other severe cardiovascular injuries. If you’ve been injured by Xolair, and are interested in participating in a class action lawsuit against the manufacturers, our lawyers can help.
FDA Warning on Xolair
Xolair, a prescription medication used to treat allergy-induced asthma, has been linked to severe cardiovascular and cerebrovascular adverse events in recent studies. According to a warning issued September 26:
“An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair.”
As a result of these problems, Xolair warning labels will be updated with information about these risks. If you are currently a Xolair user, continue taking the medication as prescribed. If you feel you may be at risk when using the drug, or notice any unusual symptoms, consult your physician immediately.